Document is current

Article History

Received: 10 September 2020

Accepted: 20 November 2020

First Online: 9 December 2020

Ethics approval and consent to participate

: The ethics review committee of Hokkaido University stated that no ethics review was necessary for this study and waived the need for formal ethics approval because it was a secondary analysis of an anonymous patient database.

: Not applicable.

: IK has received honoraria from Astellas, Daiichi Sankyo, Sumitomo Dainippon Pharma, Eisai, Eli Lilly, Janssen Pharmaceutical, Kyowa Hakko Kirin, Lundbeck, Meiji Seika Pharma, MSD, Mylan, Novartis Pharma, Ono Pharmaceutical, Otsuka Pharmaceutical, Pfizer, Shionogi, Shire, Taisho Toyama Pharmaceutical, Takeda Pharmaceutical, Tanabe Mitsubishi Pharma, Tsumura, and Yoshitomi yakuhin, and has received research/grant support from Astellas, Daiichi Sankyo, Sumitomo Dainippon Pharma, Eisai, Eli Lilly, Kyowa Hakko Kirin, Mochida Pharmaceutical, MSD, Novartis Pharma, Otsuka Pharmaceutical, Pfizer, Shionogi, and Takeda Pharmaceutical. TA received research grant from Japan Agency for Medical Research and Development, research grant from Daiichi Sankyo, scholarship funds from Biotronik Japan, Medtronic Japan, Win International, Medical System Network, and Hokuyaku Takeyama Holdings, and honoraria from Daiichi Sankyo, Ono Pharmaceutical, Boehringer Ingelheim Japan, Bayer’s Pharmaceuticals, and Bristol-Myers Squibb. KB and TN are employees of Sumitomo Dainippon Pharma. SI is an employee of CRECON Medical Assessment. CRECON Medical Assessment was paid from Sumitomo Dainippon Pharma to conduct analyses for the study.